SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
Application based on results from the TROPION-Breast01 Phase III trial
Executes the first project for developing and manufacturing a novel anticancer mAb
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Subscribe To Our Newsletter & Stay Updated
